Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tiludronate disodium
Drug ID BADD_D02218
Description Tiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid].[A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification.[A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]
Indications and Usage Tiludronic acid is indicated to treat Paget's disease of bone in patients with serum alkaline phosphatase levels ≥2 times the upper limit of normal, with symptoms, or with risk of future complications.[L4763]
Marketing Status approved; investigational; vet_approved
ATC Code M05BA05
DrugBank ID DB01133
KEGG ID D02285
MeSH ID C058651
PubChem ID 60936
TTD Drug ID D0Q8CS
NDC Product Code Not Available
UNII BH6M93CIA0
Synonyms tiludronic acid | (4-chlorophenyl)thiomethylene bisphosphonic acid | Cl2SMBP | tiludronate | (chloro-4-phenyl)thiomethylene biphosphonate | (chloro-4-phenyl)thiomethylene bisphosphonate | tiludronate disodium | Skelid
Chemical Information
Molecular Formula C7H7ClNa2O6P2S
CAS Registry Number 149845-07-8
SMILES C1=CC(=CC=C1SC(P(=O)(O)[O-])P(=O)(O)[O-])Cl.[Na+].[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Infection11.01.08.002--Not Available
Influenza like illness08.01.03.010--
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Muscle contractions involuntary17.05.03.001; 15.05.03.008--Not Available
Myalgia15.05.02.001--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Osteoarthritis15.01.04.001--Not Available
Pain08.01.08.004--
Paraesthesia17.02.06.005; 23.03.03.094--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.01.045--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tooth disorder07.09.05.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection11.01.14.004; 20.08.02.001--
Vertigo17.02.12.002; 04.04.01.003--
Vitamin D deficiency14.12.03.003--Not Available
Vomiting07.01.07.003--
Musculoskeletal discomfort15.03.04.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
The 2th Page    First    Pre   2    Total 2 Pages